The neuropeptide PACAP, injected into the eyes of diabetic rats, protected cone photoreceptors, ganglion cells, and dopaminergic neurons from diabetes-induced degeneration.
3 cell types protectedPACAP preserved cone photoreceptors, ganglion cells, and dopaminergic amacrine cells in diabetic rat retinas
What the researchers found
The neuropeptide PACAP (pituitary adenylate cyclase activating polypeptide) significantly protected the retina from diabetes-induced damage when injected into the eyes of diabetic rats. In untreated diabetic retinas, cone photoreceptors degenerated, dopaminergic nerve cells were lost, ganglion cell numbers declined, and glial cells showed stress responses.
PACAP treatment reversed these structural changes — it preserved cone photoreceptors and their outer segments, maintained ganglion cell numbers, and upregulated the PAC1 receptor and tyrosine hydroxylase (an enzyme critical for dopamine production). The protection appears to work through PACAP's PAC1 receptor.
Why it matters
Diabetic retinopathy is the leading cause of blindness in working-age adults, and current treatments focus on late-stage vascular damage. This study shows that PACAP can protect retinal neurons early in the disease process — before the blood vessel problems become severe. If neuropeptide-based therapies could be developed for the retina, they might preserve vision by preventing the neuronal damage that precedes and accompanies diabetic retinopathy.
The numbers in context
100 pmol PACAP per intravitreal injection · 3 injections over 1 week · 3-week diabetes model · Cone photoreceptors, ganglion cells, and dopaminergic cells all protected · PAC1 receptor and tyrosine hydroxylase upregulated
How the study worked
Diabetes was induced in Wistar rats with streptozotocin injection. PACAP (100 pmol) was injected directly into one eye three times during the last week of a 3-week period. Retinas were analyzed using histology, immunohistochemistry (single/double labeling and whole-mount), quantitative RT-PCR, and Western blotting to assess structural and molecular changes.
Who was studied
Male Wistar rats with streptozotocin-induced diabetes
What this study cannot tell us
This was a short-term (3-week) rat model of diabetes, which doesn't fully replicate the years-long progression of human diabetic retinopathy. Intravitreal injection is invasive and the study didn't test less invasive delivery methods. Specific quantitative data on cell counts and protein levels are in the full paper but not the abstract. No functional vision testing was reported.
How to read the evidence
Preliminary evidence from an animal study in rats. The multi-method approach (histology, immunohistochemistry, RT-PCR, Western blot) provides thorough mechanistic data, but no human studies of PACAP for diabetic retinopathy exist.
When this study was published
Published in 2012. While over a decade old, this remains an important early demonstration of PACAP's neuroprotective potential in diabetic retinopathy. The concept of treating the neural component of diabetic eye disease has gained traction since.
The bigger picture
Most diabetic retinopathy treatments target blood vessel leakage and abnormal vessel growth — the late-stage vascular problems. But researchers increasingly recognize that retinal neurons start dying early in diabetes, before obvious vascular changes. PACAP represents a neuroprotective strategy that could complement existing treatments by preserving the neurons themselves. This fits into a broader research movement toward treating the neural (not just vascular) component of diabetic eye disease.
Questions still open
- Could PACAP or PAC1 receptor agonists be delivered via eye drops instead of injections?
- Does PACAP protection persist long-term, or would ongoing treatment be needed throughout the course of diabetes?
- Would combining PACAP neuroprotection with anti-VEGF vascular therapy provide better outcomes than either alone?
Common questions
What is PACAP and how does it protect the retina?
Could this become a treatment for people with diabetic eye disease?
Read the original research
Protective effects of the neuropeptide PACAP in diabetic retinopathy.
Cell and tissue research, 348(1), 37-46
Citation
Szabadfi, Krisztina; Atlasz, Tamas; Kiss, Peter; Reglodi, Dora; Szabo, Aliz; Kovacs, Krisztina; Szalontai, Balint; Setalo, Gyorgy; Banki, Eszter; Csanaky, Katalin; Tamas, Andrea; Gabriel, Robert. (2012). Protective effects of the neuropeptide PACAP in diabetic retinopathy.. Cell and tissue research, 348(1), 37-46. https://doi.org/10.1007/s00441-012-1349-0